title: Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
abstract: OBJECTIVE
  A quantitative anti-transcription intermediary factor 1-gamma (anti-TIF1-γ) ELISA may improve the detection of cancer-associated myositis (CAM). The aims of this study were the development and validation of a quantitative anti-TIF1-γ autoantibody ELISA in patients with myositis.
  
  
  METHODS
  We developed an ELISA using recombinant purified full-length human TIF1-γ. Patient serum was incubated with TIF1-γ-coated ELISA plates, and secondary antibody that bound human IgG was used to detect anti-TIF1-γ binding. Protein immunoprecipitation (IP) was used as the gold standard for the presence of anti-TIF1-γ. Serum samples from myositis patients with positive and negative anti-TIF1-γ by IP, from non-myositis autoimmune patients (SSc, SLE and RA) and from healthy controls were analysed. The ELISA's sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were evaluated. Agreement between the ELISA and IP results was determined using chi-squared and kappa tests. Test-retest reliability of the ELISA was assessed.
  
  
  RESULTS
  We identified 55 myositis patients with and 111 controls without anti-TIF1-γ by IP. Anti-TIF1-γ positivity by ELISA showed strong agreement (93.9%) with IP results (κ = 0.87). The sensitivity, specificity, PPV, NPV and overall accuracy of the anti-TIF1-γ ELISA were 91%, 96%, 93%, 95% and 94%, respectively. The area under the curve (AUC) of a receiver operating characteristic (ROC) curve was 0.938. Test-retest reliability was strong (Pearson r = 0.913, P < 0.001).
  
  
  CONCLUSIONS
  We developed a quantitative ELISA for detecting serum anti-TIF1-γ autoantibodies and validated the assay in myositis and other connective tissue disease patients. The availability of a validated, quantitative ELISA should improve the detection of anti-TIF1-γ autoantibodies and may improve the detection of CAM.
authors.affiliation: BST S705A, 3500 Terrace Street, Pittsburgh, PA 15261, USA. aggarwalr@upmc.edu.
authors.forename: Rohit
authors.initials: R
authors.lastname: Aggarwal
authors.forename: Chester V
authors.initials: CV
authors.lastname: Oddis
authors.forename: Danielle
authors.initials: D
authors.lastname: Goudeau
authors.forename: Noreen
authors.initials: N
authors.lastname: Fertig
authors.forename: Ilinca
authors.initials: I
authors.lastname: Metes
authors.forename: Chad
authors.initials: C
authors.lastname: Stephens
authors.forename: Zengbiao
authors.initials: Z
authors.lastname: Qi
authors.forename: Diane
authors.initials: D
authors.lastname: Koontz
authors.forename: Marc C
authors.initials: MC
authors.lastname: Levesque
mesh_terms: D019540:Area Under Curve; D001323:Autoantibodies / Q000097:blood*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D009220:Myositis / Q000097:blood / Q000175:diagnosis* / Q000276:immunology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012372:ROC Curve; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014157:Transcription Factors / Q000276:immunology*
chemical_list: D001323:Autoantibodies; C511956:TRIM33 protein, human; D014157:Transcription Factors
keywords: ELISA; anti-transcription intermediary factor 1-gamma (TIF1-γ) autoantibody; development and validation of quantitative measure; idiopathic inflammatory myopathy; immunoprecipitation